Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy ...

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), reducing the price target ...

Human papillomavirus (HPV) remains one of the most prevalent viral infections globally, affecting millions across ...

A study published in Scientific Reports found that cannabidiol (CBD) disrupts lipid metabolism and induces apoptosis in ...

The pathway controls the production of heat shock ... NXP800 drug make great progress in clinical studies for ovarian cancer, so it is very exciting to see that it could potentially also benefit ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Low-grade ovarian cancer is less responsive to chemotherapy due to its slow growth. It also has fewer genetic mutations, making it less reliant on the cellular pathways that chemotherapy typically ...